• العربية
    • Biotricity, Healthcare

    Biotricity files FDA 510(k) for a new form factor of its Biotres Cardiac Monitoring Device to expand its revenue growth

    December 12, 2022

    Biotricity Inc. (Biotricity) today announced that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a new form factor of its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.

    Recent Posts

    Recent Comments

    No comments to show.
    Recent Posts
    Archives
    Categories
    Meta
    Previous
    Asep Inc. signs Letter of Intent for joint venture with Bahrain-based Seaspring W.L.L. for regulatory approval and commercialization of sepsis diagnosis technology
    Next
    Wedge Networks to participate in the upcoming Arab International Cybersecurity Summit (AICS)
    Privacy Settings
    We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
    Youtube
    Consent to display content from - Youtube
    Vimeo
    Consent to display content from - Vimeo
    Google Maps
    Consent to display content from - Google
    Spotify
    Consent to display content from - Spotify
    Sound Cloud
    Consent to display content from - Sound
    Save